Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features

[1]  J. Lubiński,et al.  Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Wicha,et al.  Getting to the root of BRCA1-deficient breast cancer. , 2009, Cell stem cell.

[3]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[4]  N. Kemeny,et al.  Colorectal hepatic metastases: adjuvant chemotherapy and survival. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Hwang,et al.  Gastrosplenic fistula from Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Tutt,et al.  Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Bernard T. Lee,et al.  Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. , 2009, Cancer research.

[8]  A. Vincent-Salomon,et al.  High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. , 2009, Cancer research.

[9]  E. Simpson,et al.  Aromatase expression is increased in BRCA1 mutation carriers , 2009, BMC Cancer.

[10]  Christopher I Amos,et al.  Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Merajver,et al.  BRCA1 regulates human mammary stem/progenitor cell fate , 2008, Proceedings of the National Academy of Sciences.

[12]  F. Couch,et al.  Response: Re: Molecular Basis for Estrogen Receptor α Deficiency in BRCA1-Linked Breast Cancer , 2007 .

[13]  L. Norton,et al.  Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis , 2007, Annals of Surgical Oncology.

[14]  I. Cousineau,et al.  BRCA1 Haploinsufficiency, but not Heterozygosity for a BRCA1-truncating Mutation, Deregulates Homologous Recombination , 2007, Cell cycle.

[15]  F. Couch,et al.  Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. , 2007, Journal of the National Cancer Institute.

[16]  Å. Borg,et al.  Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors , 2005, Modern Pathology.

[17]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[18]  L. Bégin,et al.  Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer , 2005, Clinical Cancer Research.

[19]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[20]  O. Olopade,et al.  Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer , 2004, Clinical Cancer Research.

[21]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[22]  I. Andrulis,et al.  HER‐2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry , 2002, Cancer.

[23]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Daniel Birnbaum,et al.  Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes , 1999, Cancer.

[25]  G. Giles,et al.  The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations , 1998, Cancer.

[26]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[27]  L. Norton,et al.  BRCA-associated breast cancer in young women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.

[29]  M N Pollak,et al.  Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women , 1997, Cancer.

[30]  Å. Borg,et al.  Tumour biological features of BRCA1-induced breast and ovarian cancer. , 1997, European journal of cancer.

[31]  D. Birnbaum,et al.  Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. , 1996, Cancer research.

[32]  L. R. Macfarlane,et al.  Department of pathology , 1961, Journal of the Royal Army Medical Corps.